Skip to main content
. 2023 Oct 16;31(1):e16098. doi: 10.1111/ene.16098

TABLE 2.

Baseline characteristics.

Characteristic Overall population AChR‐Ab+ participants AChR‐Ab− participants
Efgartigimod (n = 84) Placebo (n = 83) Efgartigimod (n = 65) Placebo (n = 64) Efgartigimod (n = 19) Placebo (n = 19)
Age, mean (SD), years 45.9 (14.4) 48.2 (15.0) 44.7 (15.0) 49.2 (15.5) 50.2 (11.6) 44.8 (12.6)
Sex, female, n (%) 63 (75) 55 (66) 46 (71) 40 (63) 17 (90) 15 (79)
Time since diagnosis, mean (SD), years 10.1 (9.0) 8.8 (7.6) 9.7 (8.3) 8.9 (8.2) 11.7 (11.5) 8.5 (5.2)
Total MG‐ADL score, mean (SD) 9.2 (2.6) 8.8 (2.3) 9.0 (2.5) 8.6 (2.1) 9.7 (3.1) 9.8 (2.5)
Total QMG score, mean (SD) 16.2 (5.0) 15.5 (4.6) 16.0 (5.1) 15.2 (4.4) 16.6 (4.6) 16.5 (5.2)
MGFA class at screening, n (%)
Class II 34 (40) 31 (37) 28 (43) 25 (39) 6 (32) 6 (32)
Class III 47 (56) 49 (59) 35 (54) 36 (56) 12 (63) 13 (68)
Class IV 3 (4) 3 (4) 2 (3) 3 (5) 1 (5) 0 (0)
Prior treatment with NSIST, n (%) 62 (74) 57 (69) 47 (72) 43 (67) 15 (79) 14 (74)
MG therapies at baseline, n (%)
Any AChEI 71 (85) 67 (81) 57 (88) 57 (89) 14 (74) 10 (53)
Any steroid 60 (71) 67 (81) 46 (71) 51 (80) 14 (74) 16 (84)
Any NSIST 51 (61) 51 (61) 40 (62) 37 (58) 11 (58) 14 (74)
Steroid and NSIST 43 (51) 44 (53) 34 (52) 31 (48) 9 (47) 13 (68)

No steroid or NSIST (AChEI only)

16 (19) 7 (8) 13 (20) 6 (9) 3 (16) 1 (5)

Abbreviations: AChEI, acetylcholinesterase inhibitor; AChR‐Ab, anti‐acetylcholine receptor antibody; MG, myasthenia gravis; MG‐ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; NSIST, nonsteroidal immunosuppressive therapy; QMG, Quantitative Myasthenia Gravis.